1. Home
  2. ENTA vs MPV Comparison

ENTA vs MPV Comparison

Compare ENTA & MPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • MPV
  • Stock Information
  • Founded
  • ENTA 1995
  • MPV 1988
  • Country
  • ENTA United States
  • MPV United States
  • Employees
  • ENTA N/A
  • MPV N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • MPV Finance Companies
  • Sector
  • ENTA Health Care
  • MPV Finance
  • Exchange
  • ENTA Nasdaq
  • MPV Nasdaq
  • Market Cap
  • ENTA 160.3M
  • MPV 183.8M
  • IPO Year
  • ENTA 2013
  • MPV N/A
  • Fundamental
  • Price
  • ENTA $7.28
  • MPV $19.25
  • Analyst Decision
  • ENTA Buy
  • MPV
  • Analyst Count
  • ENTA 4
  • MPV 0
  • Target Price
  • ENTA $18.00
  • MPV N/A
  • AVG Volume (30 Days)
  • ENTA 168.6K
  • MPV 25.2K
  • Earning Date
  • ENTA 08-04-2025
  • MPV 01-01-0001
  • Dividend Yield
  • ENTA N/A
  • MPV 8.71%
  • EPS Growth
  • ENTA N/A
  • MPV N/A
  • EPS
  • ENTA N/A
  • MPV 1.71
  • Revenue
  • ENTA $64,462,999.00
  • MPV N/A
  • Revenue This Year
  • ENTA N/A
  • MPV N/A
  • Revenue Next Year
  • ENTA $0.48
  • MPV N/A
  • P/E Ratio
  • ENTA N/A
  • MPV $9.35
  • Revenue Growth
  • ENTA N/A
  • MPV N/A
  • 52 Week Low
  • ENTA $4.09
  • MPV $11.18
  • 52 Week High
  • ENTA $17.24
  • MPV $16.42
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 60.14
  • MPV 74.25
  • Support Level
  • ENTA $6.87
  • MPV $18.47
  • Resistance Level
  • ENTA $8.47
  • MPV $19.32
  • Average True Range (ATR)
  • ENTA 0.50
  • MPV 0.56
  • MACD
  • ENTA -0.03
  • MPV 0.09
  • Stochastic Oscillator
  • ENTA 54.44
  • MPV 72.54

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About MPV Barings Participation Investors

Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.

Share on Social Networks: